Antibody data
- Antibody Data
- Antigen structure
- References [4]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 66926-1-Ig - Provider product page
- Provider
- Proteintech Group
- Product name
- GPNMB antibody
- Antibody type
- Monoclonal
- Description
- GPNMB antibody (Cat. #66926-1-Ig) is a mouse monoclonal antibody that shows reactivity with Human, mouse, rat and has been validated for the following applications: IF, IHC, WB,ELISA.
- Reactivity
- Human, Mouse, Rat
- Host
- Mouse
- Conjugate
- Unconjugated
- Isotype
- IgG
- Antibody clone number
- 2B10B8
- Vial size
- 20ul, 150ul
Submitted references A comprehensive evaluation of circ_0065214/ miR-188-3p/GPNMB axis in breast cancer.
PCSK9 inhibitor protects against ischemic cerebral injury by attenuating inflammation via the GPNMB/CD44 pathway.
Lactic acid-induced M2-like macrophages facilitate tumor cell migration and invasion via the GPNMB/CD44 axis in oral squamous cell carcinoma.
TROP-2, Nectin-4, GPNMB, and B7-H3 Are Potentially Therapeutic Targets for Anaplastic Thyroid Carcinoma.
Wu XX, Zhao YX, Xu SL, Wang LX, Mao JH, Wang B, Yang H
Cellular signalling 2024 Mar;115:111019
Cellular signalling 2024 Mar;115:111019
PCSK9 inhibitor protects against ischemic cerebral injury by attenuating inflammation via the GPNMB/CD44 pathway.
Zheng Y, Zhu T, Li G, Xu L, Zhang Y
International immunopharmacology 2024 Jan 5;126:111195
International immunopharmacology 2024 Jan 5;126:111195
Lactic acid-induced M2-like macrophages facilitate tumor cell migration and invasion via the GPNMB/CD44 axis in oral squamous cell carcinoma.
Lin Y, Qi Y, Jiang M, Huang W, Li B
International immunopharmacology 2023 Nov;124(Pt B):110972
International immunopharmacology 2023 Nov;124(Pt B):110972
TROP-2, Nectin-4, GPNMB, and B7-H3 Are Potentially Therapeutic Targets for Anaplastic Thyroid Carcinoma.
Toda S, Sato S, Saito N, Sekihara K, Matsui A, Murayama D, Nakayama H, Suganuma N, Okubo Y, Hayashi H, Iwasaki H, Miyagi Y, Hoshino D
Cancers 2022 Jan 24;14(3)
Cancers 2022 Jan 24;14(3)
No comments: Submit comment
No validations: Submit validation data